Tomahawk, WI 05/28/2014 (Basicsmedia) – Amgen, Inc. (NASDAQ:AMGN) and its ancillary Onyx Pharmaceuticals, Inc. declared that after a long research and several revisions on both pipeline and marketed products, the data would be presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) to be held during May 30 – June 3 in Chicago. As per the words of Sean E. Harper (MD, Executive Vice President of Research and Development at Amgen), the statistics presented at ASCO this year, would exhibit the efforts of Amgen Onyx in widening the treatment for the patients intricate to treat right now suffering from cancer, and also examining and enhancing the current requirements of cancer handlings.

Expansion Of Amgen’s Vectibix Label

After a long stop period, eventually the most anticipated Vectibix Label from Amgen, Inc. (NASDAQ:AMGN) has gained the confidence form the oncology experts and has got the green signal from the Food and Drug Administration (FDA), for its expansion in the US. From now onwards Amgen’s Vectibix drug can easily be used as a first line remedy for the patients enduring wild-type KRAS (exon 2) metastatic colorectal cancer (mCRC). The approval has been given to the Vectibix with a mishmash of oxaliplatin-based chemotherapy regimen, Folfox, which is quite effective for the patients who are suffering from genetic cancer mutation.

Amgen, Inc. (NASDAQ:AMGN) And The Stock Market

Amgen, Inc. (NASDAQ:AMGN) witnessed a disgrace, as its share slipped by a margin of -0.4% on Friday, as soon as the corporation accounted the expansion of its Vectibix drug in the US, which is used to cure patients suffering from advanced colon cancer. With this decision of the FDA, colossal drug manufacturer like Illumina, NPS Pharmaceuticals, Inc., Merrimack Pharmaceuticals, Inc. and Celgene Corporation observed a dynamic change in their shares for the intact day. With this decision will Amgen supersede and will this decision make any impact on these organizations, we will have to wait and watch. 

DISCLAIMER: This content is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.